1-5 of 5
Audrey Filézac De L'Étang
Close
Sort by
Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Martin Hutchings, Abraham Avigdor, Anna Maria Sureda Balari, Maria José Terol, Francesc Bosch, Paolo Corradini, Thomas S. Larsen, Antonio Rueda Dominguez, Alan Skarbnik, Judit Mészáros Joergensen, David Lavie, Ronit Gurion, Pier Luigi Zinzani, Antonio Pinto, Raul Cordoba, Alessia Bottos, Donghang Li, James Relf, Audrey Filézac De L'Étang, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2023) 142 (Supplement 1): 4460.
https://doi.org/10.1182/blood-2023-174213
Published: 2023
Journal Articles

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Matthew Matasar, Toby A. Eyre, Eva Gine, Audrey Filézac De L'Étang, Ben Byrne, Linda Lundberg, Alejandra Padovani, Christophe Boetsch, Alessia Bottos, Naseer Qayum
Journal: Blood
Blood (2023) 142 (Supplement 1): 3052.
https://doi.org/10.1182/blood-2023-173946
Published: 2023
Journal Articles

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella
Journal: Blood
Blood (2022) 140 (Supplement 1): 178–180.
https://doi.org/10.1182/blood-2022-157777
Published: 2022
Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2021) 138 (Supplement 1): 525.
https://doi.org/10.1182/blood-2021-148359
Published: 2021
Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella
Journal: Blood
Blood (2021) 138 (Supplement 1): 130.
https://doi.org/10.1182/blood-2021-148949
Published: 2021